Bhagirathbhai Dholaria, MBBS, of Vanderbilt University Medical Center, Nashville, TN, details how patients are selected for allogenic stem cell transplantation after chimeric antigen receptor T-cell (CAR-T) therapy. Dr Dholaria explains that patients with B-cell acute lymphoblastic leukemia (B-ALL) with certain comorbidities, recurrent measurable residual disease after CAR-T therapy, or specific molecular aberrations should be considered for allotransplantation. Additionally, patients experiencing loss of in vivo CAR-T or B-cells, or patients with hypergammaglobulinemia, are at an increased risk of relapse after CAR-T therapy. Finally, Dr Dholaria discusses how patients with prior allogenic transplantation, or those who are in remission but have previously failed CAR-T therapy, should be offered transplantation. This interview took place at the 4th Annual Meeting of the International Academy for Clinical Hematology (IACH), which took place virtually in 2021.